Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Historically Controlled Study Testing the Efficacy of TTFields (Optune®) With Adjuvant Temozolomide in High Risk WHO Grade II and III Astrocytomas (FORWARD)

NCT03906448 is registered in ClinicalTrials.gov with University of Florida as lead sponsor.

NCT NCT03906448
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03906448 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Historically Controlled Study Testing the Efficacy of TTFields (Optune®) With Adjuvant Temozolomide in High Risk WHO Grade II and III Astrocytomas (FORWARD)
Lead sponsor
University of Florida
Phase
Phase 2
Overall status
Terminated
Start date
May 20, 2019
Completion date
June 8, 2020
Enrollment
1 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

astrocytoma, grade ii, astrocytoma, grade iii